Introduction
For successful auto-SCT, infusion of an adequate number of hematopoietic stem cells is essential to achieve rapid and durable hematological recovery with less toxicity.
1,2 The conventional strategy for autologous stem cell mobilization is administration of G-CSF alone or in combination with myelosuppressive chemotherapy. 3 Many studies have sought to improve and optimize autologous stem cell mobilization and collection. Several reports have shown that autologous stem cell mobilization is more effective if chemotherapy is combined with G-CSF, compared with G-CSF alone, [3] [4] [5] and previous studies seeking to define the optimal dose of G-CSF for autologous stem cell mobilization found that G-CSF at 10 mg/kg/day was highly effective. [6] [7] [8] However, few reports on the optimal timing of G-CSF administration for autologous stem cell collection have appeared. Also, little is known regarding the short-term kinetics of G-CSF. Theoretically, autologous stem cell collection can be achieved more effectively if the plasma G-CSF concentration is sustained above the trough level. In normal healthy volunteers, it has been reported that a transient fall in GM-CSF and autologous stem cell levels occurs 1 h after injection, and recovery to baseline levels was achieved 3 h post-injection and subsequently rose to B150% of baseline at 4-12 h. 9 In another study, the plasma G-CSF level in ovarian cancer patients with chemotherapyinduced granulocytopenia started to increase immediately after the first injection of G-CSF, peaked 3-6 h later, and decreased after 12 h. 10 In our center, G-CSF used to be routinely injected at 2000 hours daily and apheresis was commenced at 0900 hours on the next day. Thus, a standard protocol for autologous stem cell collection was followed. Based on reports detailing G-CSF kinetics, 9, 10 we modified the protocol in late 2004, as we considered that changing the G-CSF injection time might positively affect the outcome of autologous stem cell collection. From November 2004, G-CSF injection was performed at 0600 hours daily.
Here we compare the efficacy of autologous stem cell collection between two patient groups differing in the timing of G-CSF injection.
Materials and methods
Patients and data collection A total of 262 patients, who underwent autologous stem cell collection at the Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, from January 2000 to March 2008, were included. Patients were diagnosed with Hodgkin's lymphoma, non-Hodgkin's lymphoma or multiple myeloma and all were eligible for auto-SCT. Data on age, gender, previous radiation therapy, number of previous chemotherapy cycles and regimens and chemotherapy regimens used for mobilization, were obtained from the auto-SCT data registry of our center. Data collected also included the total number of CD34 þ cells collected, the number of CD34 þ cells collected at first apheresis and the number of apheresis procedures.
PBPC mobilization and harvest
PBPCs were mobilized using chemotherapy followed by lenograstim (recombinant G-CSF, Choongwae Corp., Seoul, Korea), both to reduce tumor burden and to facilitate PBPC harvesting.
High-dose CY (HDC) has served as the gold standard for mobilization of PBPCs, but non-HDC regimens have also been used to this end to optimize harvest yield, as many studies have reported the efficiency of combination chemotherapy regimens (such as ESHAP or DHAP; defined below), or other regimens used as second-line therapy or salvage chemotherapy, in patients with relapsed or refractory lymphoma. [11] [12] [13] Among patients treated and mobilized with non-HDC regimens, 67 received ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin) with (n ¼ 14) or without Rituximab (n ¼ 53); 13 were treated with a modified CALGB protocol 14 (CY, VCR, high-dose MTX, ifosfamide, VP-16, Ara-C, dexamethasone and doxorubicin); 10 received high dose Ara-C; 5 were treated with DHAP (dexamethasone, high-dose cytarabine and cisplatin); 5 received CODOX-M/IVAC (CY, doxorubicin, high-dose MTX/ifosfamide, etoposide and high-dose cytarabine); 5 were treated with CYVE (high-dose cytarabine with VP-16); and 3 received ESHAOx (etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin). Other non-HDC regimens included HDC plus VP-16, CHOP and ifosfamide with VP-16.
All patients received s.c. lenograstim at 10 mg/kg once daily starting on the day after completion of mobilization chemotherapy and this continued until the last leukapheresis was completed. Patients were divided in two groups, the AM and PM group, according to lenograstim injection time. In the early phase of our study period, before November 2004, they received lenograstim at 2000 hours, about half day before apheresis (PM group), and from November 2004, patients received lenograstim at 0600 hours, 3 h before potentially planned apheresis (AM group). Circulating hematopoietic progenitor cells, enumerated by the Sysmex SE9000 (Sysmed, Chicago, IL, USA; www.sysmedlab.com), were monitored daily to determine the initiation date of PBPC collection. 15 PBPC harvest began on the day hematopoietic progenitor cell levels reached X5/mm 3 , after the nadir had been noted. PBPCs were collected using a continuous-flow blood cell separator (Fenwal CS3000 Plus, Baxter Healthcare, Deerfield, IL, USA). Each apheresis procedure was performed for B3 h, with processing of 10-14 L of blood. [16] [17] The total harvested CD34 þ cell count was monitored on each day following collection. Once initiated, leukapheresis was continued daily to achieve an optimal harvest, defined as collection of X5 Â 10 6 CD34 þ cells/kg. PBPC harvest was discontinued after optimal collection was achieved, or at least 2 days from the initiation of leukapheresis when a single apheresis resulted in o0.2 Â 10 6 CD34 þ cells/kg and the apheresis CD34 þ cell count declined. The number of CD34 þ cells in each leukapheresis harvest was determined by flow cytometry using a FACScan (Becton Dickinson, Palo Alto, CA, USA). 18, 19 Statistical analysis Patient characteristics and mobilization or apheresis variables were described, using summary statistics, as medians and ranges, or as proportions. Comparisons of analyzed parameters between groups were performed with the Mann-Whitney test for continuous variables and with the w 2 -test or Fisher's exact test for proportional variables. Multivariate analysis was done with logistric regression using diachotomized variables, such as age, diagnosis, previous radiation therapy, median number of cycles of previous chemotherapy, mobilization regimen, G-CSF injection time and BM involvement of the disease, for the average daily peripheral stem cell collection and the median number of peripheral stem cells on the first day. Patients were divided in two groups with the cutoff value of end points determined by receiver operating characteristic curve for multivariate analysis. All reported P-values are twosided, and P-values o0.05 were considered significant. Optimal timing of G-CSF for stem cell collection JE Kim et al
Results

Patient characteristics
Patient characteristics are summarized in Table 1 . Of the total of 262 patients, 129 underwent autologous stem cell collection after chemotherapy followed by lenograstim injected at 0600 hours (AM group), whereas 133 patients were injected with lenograstim at 2000 hours (PM group). Of the total study group, 150 patients were diagnosed with lymphoma and 112 with multiple myeloma. Baseline characteristics such as age, gender, diagnosis, number of previous chemotherapy regimens and the incidence of previous radiation therapy showed no significant difference between groups. In the AM group, five were received radiation to spine or pelvis, whereas eight received radiation to spine or pelvis in the PM group. Patients with lymphoma were preferentially mobilized with non-HDC regimens (74.6%), whereas the majority of multiple myeloma patients were mobilized with HDC (91.9%).
PBPC harvest
Apheresis yields for the AM and PM groups are described in Table 2 . The median number of apheresis procedures was two (range: 1-6) and three (range: 1-8) in the AM and PM groups, respectively. The median number of total CD34 þ cells/kg collected was significantly larger in the AM group, at 13.29 Â The median number of CD34 þ cells/kg collected at first apheresis was also greater in the AM group (5.34 Â 10 6 /kg vs 2.96 Â 10 6 /kg, P ¼ 0.001). The proportion of patients from whom optimal PBPC collection was achieved was significantly higher in the AM group (87.6 vs 72.2%, P ¼ 0.002).
We compared the results of PBPC harvest when patients were divided into two groups by diagnosis, the lymphoma and multiple myeloma groups. In the AM group, the higher efficacy of PBPC collection (lymphoma: 4.53 vs 2.52, P ¼ 0.030, multiple myeloma: 6.71 vs 4.64, P ¼ 0.006) with greater numbers of total CD34 þ cells/kg collected over a shorter apheresis duration was also clear in each disease group (Table 3) .
We analyzed the results of PBPCs according to mobilization regimen. In patients where HDC was used as the mobilization regimen, higher efficacy of PBPC collection (6.75 vs 2.88, AM vs PM group, Po0.0001), with greater numbers of total CD34 þ cells/kg collected (16.82 vs 9.49 Â 10 6 /kg, Po0.0001), higher number of CD34 þ cells/kg collected (6.75 vs 2.88 Â 10 6 /kg, Po0.0001) and a larger proportion attaining optimum collection (92.9 vs 69.4%, P ¼ 0.001) were observed in the AM group. On the other hand, a similar trend without statistical significance was observed in patients used non-HDC as the mobilization regimen (Table 4) . Comparing the results according to mobilization regimens by diagnosis, statistically significant differences in results of PBPC collection according to Table 2 Results of PBPC harvest (N ¼ 262) 
Table 3
Harvest of PBPCs according to disease G-CSF injection time were observed only in myeloma patients where HDC was used as the mobilization regimen. The number of multiple myeloma patients who used non-HDC as mobilization was small (two patients in the AM group and nine patients in the PM group) and no statistically significant differences of PBPC collection were observed. In the lymphoma patients, the higher efficacy of PBPC collection with greater numbers of total CD34 þ cells/kg collected over a shorter apheresis duration in the AM group was observed, irrespective of the mobilization regimen, but the differences between groups (AM and PM group) were not statistically significant.
Multivariate analysis of factors affecting stem cell collection
The cutoff values of the average number of CD34 þ cells/kg of peripheral stem cell collections and the number of CD34 þ cells/kg collected on the first day to predict optimum harvest were determined with receiver operating characteristic curve consisting of plots representing a combination of sensitivity and specificity as a function of cutoff values. To compare the average daily collection, patients were divided in two groups with the cutoff value of, CD34 þ cell/kg X1.405 Â 10 6 or o1.405 Â 10 6 . Cutoff values had a sensitivity 85.7% and specificity 98.1%. Age, diagnosis, median number of cycles of previous chemotherapy, previous radiation therapy, mobilization regimen, G-CSF injection time and BM involvement were compared in univariate analysis (Table 5 ). According to the result of multivariate analysis with logistic regression based on the results of univariate analysis, the number of cycles of previous chemotherapy (hazard ratio, 3.223) and G-CSF injection time (hazard ratio, 2.225) were significant factors affecting average daily collection (Table 6 ). In the yield of peripheral stem cell collection on day 1, patients were divided in two groups with the cutoff value of CD34 þ cells/kg X1.020 Â 10 6 or o1.020 Â 10
6
, determined by receiver operating characteristic curve with a sensitivity of 89.4%, and specificity 94.2%. On univariate and multivariate analyses (Table 7) , numbers of cycles of previous chemotherapy (hazard ratio, 3.050) and G-CSF injection time (hazard ratio, 2.225) were also determined as significant factors affecting yield of peripheral stem cell collection on day 1 (Table 8) .
Discussion
The best timing for G-CSF administration remains to be defined despite many reported attempts to improve and optimize PBPC collection and mobilization. [3] [4] [5] [6] [7] Little information is available on the short-term kinetics of G-CSF and most reports are observations of the short-term effects of G-CSF in healthy volunteers. 7, 9, 20, 21 In the current study, we aimed to investigate whether the timing of G-CSF administration before apheresis affected the efficacy of autologous stem cell collection.
Our results show that G-CSF injected 3 h before planned apheresis was more efficient, with greater numbers of total CD34 þ cells/kg collected, over a shorter duration of Table 4 Results of PBPCs according to mobilization regimens (N ¼ 261) leukapheresis, than G-CSF injected about half a day before apheresis. Moreover, analysis of data according to disease (lymphoma or multiple myeloma) disclosed that for each disease type, the efficacy of PBPC collection was also better in the AM group. With the analysis of PBPC collection according to mobilization regimens, the advantage of G-CSF injection 3 h before apheresis was observed only in multiple myeloma patients where HDC was used to mobilize. The trend of greater numbers of total CD34 þ cells/kg collected over a shorter apheresis duration in the AM group was also observed in lymphoma patients irrespective of mobilization regimen, but the differences between groups were not statistically significant. The effect of G-CSF injection time to improve the yield of average daily peripheral stem cell collection and peripheral stem cell collection on the first day was also confirmed on multivariate analysis. These differences might result from different plasma G-CSF levels during leukapheresis. According to previous reports, a common feature of the short-term kinetics of G-CSF was that the plasma G-CSF level began to increase above the trough level 3 h after administration and decreased after 12 h. 9 The plasma G-CSF level might therefore be higher in the AM group during leukapheresis.
There are some limitations in this study. As a retrospective analysis, factors that might influence PBPC collection levels, such as variation in chemotherapy cycles, and the number of previous chemotherapy and mobilization regimens, were not exactly matched between groups. However, all patients included underwent PBPC mobilization and collection using the same protocol except for G-CSF administration time, and no significant betweengroup differences in baseline characteristics were noted. Moreover, subgroup analysis yielded similar data in that analysis of multiple myeloma patients mobilized by HDC revealed that G-CSF administration timing affected the efficiency of PBPC collection. As plasma G-CSF levels were not measured, the results of the current study should be interpreted with caution. The striking improvement in autologous stem cell collection efficacy achieved simply by changing the G-CSF administration time might suggest that collection efficacy reflects plasma G-CSF level during autologous stem cell collection. But although the advantage of G-CSF administration 3 h before apheresis was apparent in patients receiving high-dose CY for mobilization in further analyses according to mobilization regimen, this effect might not hold true for patients having other combination chemotherapy or G-CSF alone for mobilization. It is difficult to predict whether the same effect of our Table 6 Proportional hazard model for average daily peripheral stem cell collection
Variables
Hazards ratio (95% CI) P-value whereas higher filgrastim levels than lenograstim levels on day 1 were observed by Watts et al. 9 Further comparative analysis for lenograstim and filgrastim with measurements of plasma G-CSF levels is needed.
Moreover, the applicability of current practice is unknown for the patients treated with lenalidomide, which is the most common drug used for induction therapy and can impact upon stem cell collection. 22, 23 Lenalidomide is not yet used as standard treatment for myeloma in Korea because of the expense.
It remains controversial whether improved autologous stem cell collection efficacy improves auto-SCT outcomes, including engraftment kinetics, OS and disease-free survival. [24] [25] [26] However, with improvement of collection efficacy, probability of autologous stem cell collection failure can be reduced, and frequency of optimal collection increased.
As successful autologous stem cell mobilization and collection are influenced by various factors, such as age, BM involvement by disease, previous therapy with chemotherapeutic agents toxic to stem cells and radiotherapy, it is difficult to assess the role of G-CSF itself in autologous stem cell mobilization. 4 Further prospective studies with monitoring of plasma G-CSF levels are needed to confirm our observation and to delineate the short-term kinetics of G-CSF. The detailed process of autologous stem cell mobilization by G-CSF following chemotherapy in patients with malignancy requires further exploration.
In conclusion, G-CSF injection 3 h before apheresis resulted in the better efficacy of PBPC collection, with greater numbers of total CD34 þ cells/kg collected, over a shorter apheresis duration, and higher numbers of CD34 þ cells/kg collected on first apheresis in patients with lymphoma and multiple myeloma.
